Although an IFN-β-mediated increase in microglial FAO acid oxidation has not been empirically determined, IFN-β is a well-known therapy for MS, and patients undergoing therapy show in an increase in FAO in peripheral myeloid cells (Croze et al., 2013). This evidence concerns the gene IFNB1 and myeloid sarcoma.